Module 7: Treatment of Tobacco Use Disorder in Primary Care
Note: Following this module’s development, we were given approval to change the term “Medication Assisted Treatment (MAT)” to “Medications for Addiction Treatment (MAT)” or “Medications for Opioid Use Disorder (MOUD). ” We support this change and have begun to implement throughout our educational trainings, resources and website as we move forward.
Presenter: Jill M. Williams, MD | Professor Psychiatry; Director, Division Addiction Psychiatry; Robert Wood Jonson Medical School
Cost: No Fee
Target Audience: Physicians, nurses, and healthcare teams who are treating patients with substance use disorder (SUD).
Credit Designations Available: Interprofessional Continuing Education credit, AMA PRA Category 1 Credits™, and Nursing Contact Hours.
Core Competencies as a result of participating in this activity:
Interpersonal Skills and Communication
Module Description: Tobacco use disorder is still a major cause of preventable death that affects individuals with mental illness or other addictions to a great degree. Treatments are effective yet underutilized. Practice guidelines recommend that all smokers trying to quit should use pharmacotherapy as a first-line treatment. However, reviews suggest that use is much less; fewer than one out of every 3 smokers who try to quit uses an FDA-approved smoking cessation medication. Tobacco withdrawal causes clinically significant symptoms of agitation, anxiety, restlessness, and impaired concentration. Medications are effective in reducing these withdrawal symptoms and at least doubling the smoker’s chance of success in quitting smoking. Pharmacotherapy may be even more important in smokers with mental illness or other addictions as they have higher levels of dependence than other smokers. This educational activity will review updates in evidence based treatments for tobacco use disorder.
At the conclusion of this activity participants should be able to:
- Recognize the effect of toxicity from combustible tobacco
- Identify the available quick forms of clinical assessment, including the utility of the Time to First Cigarette measure (TTFC)
- Demonstrate knowledge of pharmacotherapies for tobacco use disorder treatment, highlighting the safety and efficacy of each
- Describe nicotine replacement treatment dosing and how to enhance its effectiveness in patients
- Review the role of counseling in increasing the success of quit attempts and describe the Ask, Advise and Refer model for Primary Care
Method of participating in the learning process
In order to receive maximum credit, learners must:
1. Review the materials provided in this module.
2. Earn a minimum cumulative score of 80% on the post-test.
3. Complete an evaluation to assess satisfaction and plans for individual and/or team practice change.
4. Follow instructions at the end of the course regarding how to retrieve a certificate.*
*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.
Accreditation and Certification of this activity
Joint Accreditation Statement
In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
In 2019, AAAP also added accreditation from The American Academy of PAs (AAPA), American Psychological Association (APA) and Association for Social Work Boards (ASWB).
Release Date: July 26, 2019 Date of Expiration: July 26, 2022
Interprofessional Continuing Education (IPCE) Designation Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education credit for learning and change.
Physician Designation Statement
American Academy of Addiction Psychiatry designates this performance improvement activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Designation Statement
American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP's Joint Accreditation provider #4008192. This program is approved for up to 1.5 Nursing Contact Hours.
AAAP's interprofessional continuing education program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. During the planning process, anyone that is involved in the content is required to disclose to AAAP and our learners any real or potential conflict of interest related to the educational activity. The following individuals have no relevant financial relationships with an ACCME defined commercial interest to disclose: Thomas Penders, MD, Michael Goedde, MD, Nitigna Desai, MD, Karen Oliver, PhD, John Renner, Jr, MD, Kevin Sevarino, MD, PhD, Kathryn Cates-Wessel, Miriam Giles, Carol Johnson, Jennifer Lundstrom, and Justina Pereira. PCSS Clinical Expert Committee members and content reviewers David Fiellin, MD, Michelle Lofwall, MD, Larissa Mooney, MD, and Colleen LaBelle, MSN, RN-BC, CARN, have nothing relevant to the content of this module to disclose. Content Developer, Jill M. Williams, MD, disclosed that she received grant support from Pfizer on a tobacco-related grant. This has been determined not to conflict with presentation content.
Faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Learners are advised that this activity may contain references to unlabeled uses of US FDA-approved products or to products not approved by the FDA for use in the United States. In these instances, participants will be made aware of such usage and discussions regarding either non–FDA-approved or investigational use of products/devices.
ADA Accommodation Statement
AAAP encourage persons with disabilities to participate in our programs and activities. If you anticipate needing any type of accommodation or have questions about this activity, please email email@example.com.
Privacy and Confidentiality Policy
AAAP values your privacy and confidentiality of the information you choose to share with us. Personal information collected from evaluations will not be shared with third parties.
Disclaimer: The views, opinions, and content expressed herein do not necessarily reflect the views or policies of AAAP, CSAT, SAMHSA, or HHS. No official support of or endorsement by AAAP, CSAT, SAMHSA, or HHS for these opinions or for particular instruments, software, or resources is intended or should be inferred.
Support for the Program:
Funding for this initiative was made possible (in part) by grant no. 5U79TI026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.